Timothy J Finnegan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Timothy J Finnegan has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Lisa A Carey
The University of North Carolina, Division of Hematology/Oncology, CB#7305, 3009 Old Clinic Building, Chapel Hill, NC27599, USA
1 shared publication
Latest Publications
- 5 February 2007
- Published by Taylor & Francis in Future Oncology
- Vol. 3 (1) , 55-63
Gene-Expression Analysis and the Basal-Like Breast Cancer Subtype
Analysis of the patterns of gene expression in breast cancer suggests that it is not a single entity, but is comprised of several biologically distinct subtypes with characteristic molecular profiles. These molecular profiles confirm the clinical impression that estrogen receptor (ER)-negative differs from ER-positive, and expands our understanding by identifying breast cancer subtypes, including the basal-like and human epidermal growth factor receptor (HER)2/ER subtypes within the ER-negative subset, and the luminal A and B subtypes within ER-positive disease. The basal-like subtype is characterized by the low expression levels of the ER-related and the HER2-related group of genes, and therefore is often 'triple negative' on clinical assays for these proteins. This review discusses the molecular profiles of breast cancer with a focus on the clinical characteristics of, and treatment options for, the basal-like subtype.
- 5 February 2007
- Published by Taylor & Francis in Future Oncology
- Vol. 3 (1) , 55-63
Gene-Expression Analysis and the Basal-Like Breast Cancer Subtype
Analysis of the patterns of gene expression in breast cancer suggests that it is not a single entity, but is comprised of several biologically distinct subtypes with characteristic molecular profiles. These molecular profiles confirm the clinical impression that estrogen receptor (ER)-negative differs from ER-positive, and expands our understanding by identifying breast cancer subtypes, including the basal-like and human epidermal growth factor receptor (HER)2/ER subtypes within the ER-negative subset, and the luminal A and B subtypes within ER-positive disease. The basal-like subtype is characterized by the low expression levels of the ER-related and the HER2-related group of genes, and therefore is often 'triple negative' on clinical assays for these proteins. This review discusses the molecular profiles of breast cancer with a focus on the clinical characteristics of, and treatment options for, the basal-like subtype.